Latest Conference Articles

Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.

Patients with atrial fibrillation and renal disease who were treated with rivaroxaban (Xarelto) had less of a risk of fatal bleeding, according to a study presented at the American Heart Association Scientific Session.

Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis and pulmonary embolism. Researchers found that the most common treatment remains parenteral anticoagulant with warfarin despite the arrival of a the new treatment option rivaroxaban.

Using rivaroxaban in a patients with non-valvular atrial fibrillation can reduce rates of stroke and major bleeding, according to the result of the XANTUS study.

Primary clinical reviewers from the FDA and 2 clinician experts provided their unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma: daratumumab (Darzalex), ixazomib (Ninlaro), and elotuzumab (Empliciti).

Results from a subgroup analysis of the phase 3 ENDEAVOR study and a phase 2 study in diffuse large B cell lymphoma patients were presented at the annual meeting of the American Society of Hematology.

Members from the American Society of Hematology (ASH)'s Choosing Wisely Task Force presented 5 recommendations on Monday, December 7, 2015, at the 57th annual meeting of ASH, in Orlando, Florida.

On the second day of the annual meeting of the American Society of Hematology, physicians got together to discuss the real-world needs of alternate payment models in hematology.

During a health outcomes session on the second day of the American Society of Hematology meeting, data presented from a study conducted at the University of Nebraska Medical Center suggested that the site of care bears a significant influence on the outcomes of patients with acute lymphoblastic leukemia.

Presenters at an education session, titled Patient-Reported Outcomes in Hematology, addressed the importance of embracing the patient perspective in healthcare delivery, on the second day of the annual meeting of the American Society of Hematology, being held December 5-8, in Orlando, Florida.

At the annual meeting of the American Society of Hematology, providers brooded over implications of quality measures and how they will influence clinical practice in the coming years.

An early session on the first day of the annual meeting and exposition of the American Society of Hematology, being held December 5-8, 2015, in Orlando, Florida, saw presentations on the promise of newly approved hematology/oncology agents, in addition to the challenges that clinicians face in treating patients with these drugs.

In a session at the Fall Managed Care Forum 2015, in Las Vegas, Nevada, cardiology expert Harold Bays MD, FTOS, FACC, FACE, FNLA, emphasized the importance of greater adherence to evidence-based practice guidelines, and the relevance of treatment with omega-3 fatty acids in hypertriglyceridemia.

Pulmonary arterial hypertension (PAH) is characterized by nonspecific symptoms, which can lead to a delay in diagnosis. Without treatment, patients with PAH have a poor prognosis, but development and availability of PAH-specific therapies have improved the overall prognosis of the disease.

The Medicare Shared Savings Program is the perfect way for primary care physicians to get involved with alternative payments as Medicare moves to replace fee-for-service, explained Hymin Zucker, MD, chief medical officer of the Triple Aim Development Group.

Panelist discuss early referral to palliative care, enduring misconceptions, culture considerations, and more at the Fall Managed Care Forum 2015.

A look at effective anticoagulation strategies for stroke prevention in patients with atrial fibrillation.

There is an enormous medication adherence problem in the United States, and millions of people could benefit from cognitive therapy, and technology can help.

As the healthcare industry positions itself for the change to value-based care, there needs to be a widespread change in terms of collaboration between physicians, hospitals, and payers.

The government is leading the charge toward value-based care and no matter how slowly, everyone else will follow, said Jacque Sokolov, MD, chairman and CEO of SSB Solutions, during the opening keynote presentation at the Fall Managed Care Forum 2015.

Results released by Sanofi and Regeneron of their PCSK9 inhibitor were based on prior clinical trials.

Studies at the American Heart Association show very different approaches to exercise for type 2 diabetes patients.

Test results presented have implications for patients if they require emergency surgery.

Results show that bleeding was the most common reason patients stopped taking the drug in this study of long-term tolerability.

Commentators called the study the most important blood pressure research in 40 years. Treating systolic pressure to a target of 120 mm Hg did not cause problems for patients with existing chronic kidney disease although there were some signals for those who did not have the disease at baseline.

More details are revealed on the first diabetes drug shown to have a cardioprotective benefit, but Yale's Silvio Inzucchi was cautious about assuming the effect applies to the entire SGLT2 inhibitor class.

Studies that measure the effect of walkable communities in Canada and taking the train in Japan show that added steps to one's routine can have positive effects on heart health.

A study finds that a commonly prescribed therapy reduces activity in patients with heart failure with preserved ejection fraction.